Supp. Figure 1 : ZOL induces CLU expression in osteosarcoma xenograft model. HOS-MNNG tumor cells were injected in paratibial site. Once tumors were palpable, mice were randomly assigned to vehicle (PBS) or ZOL (50ug/kg, s.c.) treated every two days. Mice were treated for 18h, 48h, 7 days or 7 days followed by withdrawal of ZOL for 7 days. Tumors were collected and CLU expression was evaluated by immunohistochemical analysis.
Supp. Figure 2: CLU inhibition sensitizes resistant tumor cells to ZOL, while transient overexpression of CLU protects osteosarcoma tumor cells from ZOL inhibitory effect. A,
HOS-MNNG cells were treated with increased doses of ZOL for 6 months to become resistant to ZOL (HOS-MNNG-R). After this time, the selected cells were 'pooled', in order to avoid clonality. HOS-MNNG-R and HOS-MNNG were treated with ZOL for the indicated doses for 48h. Cell growth was determined by crystal violet and compared with control. B, MG63/MG63R and HOS-MNNG/HOS-MNNG-R cells were treated twice with 300nM OGX-011 or control ScrB ASO, followed by 10µM ZOL for 48h. Then, the cells were plated without any treatment at clonal density for colony counts after coloration with crystal violet. C, MNNG/HOS osteosarcoma cells were transiently transfected with empty-or CLU-plasmid for 48h to overexpress CLU, versus an empty vector as a control (-mock) . 
